)
)
ADC Therapeutics Investor Relations Material
Latest events
Study Update
ADC Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from ADC Therapeutics SA
Access all reports
ADC Therapeutics SA is a biotechnology company specialized in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. Its proprietary technology focuses on highly potent, targeted therapies designed to significantly improve patient outcomes by selectively targeting and killing cancer cells. One of the key products offered by ADC Therapeutics is Zynlonta, a CD19-directed ADC for the treatment of certain types of B-cell lymphoma in adult patients. This focus on ADC technology highlights the company's commitment to advancing cancer treatment through innovation. The company is headquartered in Lausanne, Switzerland, and its shares are listed on the NYSE.
Key slides for ADC Therapeutics SA
Study Update
ADC Therapeutics SA
Q1 2024
ADC Therapeutics SA
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
ADCT
Country
🇺🇸 United States